Q-omics provides the consensus-scored KDM2B-DT profile across patient tissues and cancer cell-line models. KDM2B-DT expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KDM2B-DT is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KDM2B-DT RNA expression shows 19,336 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where KDM2B-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM2B-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM2B-DT survival associations across molecular data types. KDM2B-DT RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM2B-DT RNA expression–survival associations across cancer types. High KDM2B-DT expression shows unfavorable associations in KIRC, LIHC and LUSC, but favorable associations in BRCA, HNSC and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for KDM2B-DT RNA expression.
This table summarizes KDM2B-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KDM2B-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM2B-DT shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP, LUSC, LIHC and CHOL. The KIRC box plot shows higher KDM2B-DT RNA expression in tumor versus normal tissue (log2 FC = +0.457, t-test p < 0.001).
This table shows molecular features associated with KDM2B-DT in patient tissues and cancer cell lines. In patient samples, KDM2B-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
